Immunomodulatory activities of α-mangostin on peripheral blood mononuclear cells

Department of Microbiology, Faculty of Pharmacy, Mahidol University, Bangkok 10400, Thailand.
Natural product communications (Impact Factor: 0.91). 09/2013; 8(9):1257-60.
Source: PubMed


Mangosteen (Garcinia mangostana L.) a tropical fruit, has been used in traditional medicine. A frequently used part of mangosteen is the pericarp, containing a high content of xanthones. alpha-Mangostin, one of the major xanthone derivatives, exhibits a variety of actions, including antimicrobial, antioxidant, cytotoxic and antitumor; however, its function on the immune system is still equivocal. This study aimed to examine the immunomodulatory activities of alpha-mangostin on lymphocyte lineage and cytokine production in human peripheral blood mononuclear cells (PBMCs). The cytotoxic activity of alpha-mangostin was measured by MTT assay. The concentration of alpha-mangostin at 5.55 microg/mL resulted in a 50% survival of PBMCs, which was as potent a cytotoxic activity as that of paclitaxel. After 24 h of PBMCs culture, the percentages of T cells (CD3+), B cells (CD19+) and NK cells (CD3-CD16+CD56+) were not significantly changed by treatment with 1, 2 and 4 microg/mL of alpha-mangostin compared with untreated-PBMCs; in addition, the percentages of these lymphocytes treated with the combination of alpha-mangostin (1, 2 and 4 microg/mL) and the mitogen concanavalin A (ConA) was not significantly different from that of ConA-treated PBMCs. For cytokine secretion, alpha-mangostin (1, 2 and 4 microg/mL) did not significantly induce either proinflammatory cytokines (i.e., TNF-alpha and IL-1beta) or cytokine of adaptive immunity (i.e., IL-2). The combination of alpha-mangostin (1, 2 and 4 microg/mL) and ConA did not significantly alter the relative difference of TNF-alpha and IL-1beta compared with ConA-treated PBMCs; however, these combinations could significantly decrease the relative difference of IL-2 compared with ConA-treated PBMCs. These data indicated that alpha-mangostin was able to inhibit IL-2 release without interfering with human immune cells; therefore, further studies are necessary to investigate its effect on IL-2 production.

Download full-text


Available from: Supachoke Mangmool, May 18, 2015
  • [Show abstract] [Hide abstract]
    ABSTRACT: Medical herbalism has been popularized due to its reported efficacy, lesser side effects and synergistic interactions against complex syndromes. Herbal medicines are used in neurological disorders in ancient traditional systems in India, China, Japan and Korea. We retrieved and analyzed the research into anti-Huntington's neuroprotective therapeutics from plant sources investigated in neurotoxic models and transgenics in vitro and in vivo studies to provide future references for basic, pre-clinical and clinical research. The extracts, fractions and herbal compounds were summarized from popular scientific search engines and were analyzed according to their source and bioactivity. A total number of 10 plant extracts or fractions belonging to 10 species, 10 genera and 10 families, 24 active compounds and two herbal formulations were found to possess anti-HD activity via modulating a number of key signaling pathways and events implicated to HD pathogenesis. Herbal extracts/fractions and formulations exhibiting positive results in neurotoxic HD models need to be characterized for active components and underlying mechanisms of action. Plants such as Bacopa monnieri, Centella asiatica, Cannabis sativa,Gastrodia elata, Ginkgo biloba, Panax ginseng,Withania somnifera etc. were cited as the most promising anti-HD candidates, many of which are known CNS-active drugs. Anti-HD compounds include curcumin, epigallocatechin-gallate, ginsenosides, kaempferol, naringin, resveratrol, S-allylcysteine etc. some of which are well known as neuroprotectants. Further research is still needed to evaluate the therapeutic efficacy of the already known as well as the novel herbal extracts and compounds in HD models.
    Journal of Herbal Medicine 01/2015; 5(1). DOI:10.1016/j.hermed.2015.01.002 · 1.19 Impact Factor